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Adolescent olanzapine sensitization is correlated with 
hippocampal stem cell proliferation in a maternal immune 
activation rat model of schizophrenia
Shinnyi Chou, Sean Jones, and Ming Li*
Department of Psychology, University of Nebraska-Lincoln, USA
Abstract
Previous work established that repeated olanzapine (OLZ) administration in normal adolescent 
rats induces a sensitization effect (i.e. increased behavioral responsiveness to drug re-exposure) in 
the conditioned avoidance response (CAR) model. However, it is unclear whether the same 
phenomenon can be detected in animal models of schizophrenia. The present study explored the 
generalizability of OLZ sensitization from healthy animals to a preclinical neuroinflammatory 
model of schizophrenia in the CAR. Maternal immune activation (MIA) was induced via 
polyinosinic:polycytidilic acid (PolyI:C) administration into pregnant dams. Behavioral 
assessments of offspring first identified decreased maternal separation-induced pup ultrasonic 
vocalizations and increased amphetamine-induced hyperlocomotion in animals prenatally exposed 
to PolyI:C. In addition, repeated adolescent OLZ administration confirmed the generalizability of 
the sensitization phenomenon. Using the CAR test, adolescent MIA animals displayed similar 
increase in behavioral responsiveness after repeated OLZ exposure during both the repeated drug 
test days as well as a subsequent challenge test. Neurobiologically, few studies examining the 
relationship between hippocampal cell proliferation and survival and either antipsychotic exposure 
or MIA have incorporated concurrent behavioral changes. Thus, the current study also sought to 
reveal the correlation between OLZ behavioral sensitization in the CAR and hippocampal cell 
proliferation and survival. 5′-bromodeoxyuridine immunohistochemistry identified a positive 
correlation between the magnitude of OLZ sensitization (i.e. change in avoidance suppression 
induced by OLZ across days) and hippocampal cell proliferation, and a negative correlation 
between OLZ sensitization magnitude and hippocampal short term cell survival. The implications 
of the relationship between behavioral and neurobiological results are discussed.
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INTRODUCTION
The use of antipsychotic drugs (APD) in children and adolescents has increased dramatically 
worldwide in recent years (Aparasu and Bhatara, 2007; Kalverdijk et al, 2008; Rani et al, 
2008; Wong et al, 2004). APD use for patients under the age of 18 now accounts for about 
15% of total usage in the U.S., not only for the management of psychosis, but also for 
bipolar disorder, depression, disruptive behavior, and anxiety (Domino and Swartz, 2008). 
Clinical studies have established that children and adolescents tend to be more susceptible 
than adults to the adverse consequences of APD use, including prolactin elevation and motor 
side effects (Haddad and Sharma, 2007; Wudarsky et al, 1999). Preclinical studies in animal 
models suggest that this may be due to the differential biological effects APD have on 
adolescents versus adults (Choi et al, 2010; Spear et al, 1980). For instance, chronic 
treatment of various APD for 21 days significantly reduced the number of dopamine (DA) 
D1 receptors in both the medial prefrontal (mPFC) and dorsolateral frontal cortices of 
adolescent rats, but not adult rats. In contrast, DA D2 receptor levels were elevated in the 
mPFCs of adult rats after chronic APD infusion, but not in adolescent rats (Moran-Gates et 
al, 2006).
Animal studies have also illustrated that application of APD during adolescence, a critical 
period for neurodevelopment, can stimulate neuronal and behavioral functional changes that 
are reflected in adulthood (Vinish et al, 2013). Adolescent rats chronically exposed to the 
atypical APD olanzapine (OLZ) therapy released significantly less DA upon stimulation 
during adulthood than vehicle treated rats. Interestingly, our group has also shown that 
adolescent APD exposure (postnatal days [P] 35–60, Andersen et al., 2000) can increase 
APD response in adulthood, a phenomenon known as “antipsychotic sensitization” (Qiao et 
al, 2013a, 2013b, 2014). Although not well understood, APD behavioral sensitization due to 
chronic treatment is well documented. For example, the exponential curve of psychotic 
symptoms improvement over the first 4 weeks of treatment; the antipsychotic effect growing 
with the passage of time (i.e. time-dependent sensitization), and the worsening of 
extrapyramidal side effects after years of medication are all well-known demonstrations of 
APD sensitization (Agid et al, 2003; Fallon and Dursun, 2011; Kapur et al, 2006). 
Clinically, APD sensitization may play an important implication in prescription 
considerations, especially after drug abstinence. Furthermore, concerning the adolescent 
patient population, APD sensitization may interact with developmental trajectories to alter 
adulthood behavior and brain functions.
In a previous study, we showed that OLZ, an APD widely prescribed in the adolescent 
population, induces an increased behavioral sensitivity over repeated treatment during 
adolescence (Pakyurek et al, 2013). This increase in sensitivity remains evident when rats 
are re-exposed to OLZ in adulthood (Qiao et al, 2013a). The study employed the rat 
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conditioned avoidance response (CAR) test to measure APD response. This test is widely 
used and well-validated for assessing APD activity in rodents, and numerous studies have 
verified that clinically relevant doses of APD suppress avoidance behavior in animals 
(Wadenberg and Hicks, 1999; Wadenberg, 2010; Wadenberg et al, 1997). The model is 
commonly used to predict the clinical potency of APD, and thus an ideal measure of 
behavioral sensitization over repeated exposure (Arnt, 1982; Wadenberg et al, 2001).
One mechanism that may be associated with long term APD sensitization is drug-induced 
changes in cell proliferation and survival. While the effects of APD on cell growth are still 
inconsistent across studies, long-term administration of APD has been reported by some to 
increase cell proliferation in the subventricular zone as well as the subgranular zone of the 
hippocampus in adult animals (Halim et al, 2004; Keilhoff et al, 2010; Maeda et al, 2007; 
Wakade et al, 2002; Wang et al, 2004). However, no prior study has considered this effect 
of APD as a potential mechanism of APD sensitization in adolescence. Also, much of our 
APD sensitization work has used otherwise healthy rats, and it remains to be elucidated 
whether APD sensitization is generalizable and can also be demonstrated in preclinical 
disease models. In the present study, we addressed this issue by testing OLZ in a rat 
maternal immune activation (MIA) model of schizophrenia, a well-studied model that 
gained much popularity in the recent decade (Meyer and Feldon, 2010). Adult rodent 
offspring born to infected mothers displayed specific histological and behavioral 
abnormalities relevant to those seen in human patients with schizophrenia, including 
increased prefrontal cortical pyramidal cell density (Fatemi et al, 1999), deficits in learning 
(Shi et al, 2003), sensorimotor gating (Wolff and Bilkey, 2008), latent inhibition 
(Zuckerman and Weiner, 2003), and working memory (Ozawa et al, 2006).
Examination of hippocampal cellular changes associated with OLZ sensitization using a 
preclinical model is relevant to the treatment of schizophrenia. First, impaired hippocampal 
cell proliferation is thought to contribute to cognitive deficits in schizophrenia, and 
induction of hippocampal cell growth has been suggested as a possible therapeutic 
mechanism of APD treatment (Kempermann et al, 2008; Reif et al, 2006, 2007; Toro and 
Deakin, 2007). However, it is unclear whether the induction of cell proliferation by 
antipsychotics is related to behavioral phenotypes that are representative of drug efficacy. 
Secondly, MIA as a preclinical model of schizophrenia has been shown to reduce 
neurogenesis in some studies, and one previous study suggested that APD treatment may 
reverse this dysfunction (Cui et al, 2009; Piontkewitz et al, 2012b; Vuillermot et al, 2010; 
Wolf et al, 2011). However, no study has connected this cellular change in MIA animals 
with behavioral effects, which warrants the current idea of examining the relationship 
between cell proliferation and survival associated with APD treatment and the CAR 
behavior observed in a preclinical model.
In this study, we investigated the potential connection between the induction and expression 
of OLZ sensitization in adolescent rats and OLZ-induced cell proliferation and survival in 
the dentate gyrus (DG) of rat hippocampi, using the CAR task for behavioral assessment and 
5′-bromodeoxyuridine (BrdU) immunohistochemistry for cellular examination, respectively. 
In addition, various behavioral assays were used to assess MIA-induced behavioral 
impairments. These included maternal separation-induced 40 kHz pup ultrasonic 
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vocalizations (USV) on P11, an assay for early communicative behavior and stress response 
(Ming et al, 2011); prepulse inhibition (PPI) in adolescence (P43), an assay for sensorimotor 
gating ability (Geyer and Braff, 1987; Swerdlow et al, 2008); and amphetamine-induced 
hyperlocomotion in adulthood (P84), an assay for both DAergic defect as well as APD 
efficacy (Arnt, 1995; Laruelle et al, 1996, 1999). In assessing ultrasonic vocalizations, we 
expect MIA animals to exhibit decreased total number of vocalizations after maternal 
separation, as previous studies have indicated communication deficits in MIA offspring 
using a similar paradigm (Malkova et al, 2012). While PPI results have been somewhat 
inconclusive regarding MIA offspring assessments due to variations in experimental 
procedure, we hypothesize a deficit in sensory-motor gating based on previous report using 
parameters similar to the current study (Wolff and Bilkey, 2010). Finally, Zuckerman et al, 
2003 previously reported an increase in amphetamine-induced hyperlocomotion in adult 
MIA offspring, and we hypothesize a similar finding in the current study.
Thus, the overall goals of the study were twofold. First, we sought to identify whether OLZ, 
an APD widely prescribed in the adolescent population, produces behavioral sensitization in 
adolescent MIA animals. This confirms whether the adolescent OLZ sensitization 
phenomenon in healthy animals can generalize into a preclinical animal model of psychiatric 
disorders. Secondly, we also sought to investigate whether changes in cell proliferation and 
survival in the DG of the hippocampus are associated with the CAR sensitization induced by 
repeated OLZ exposure. We hypothesized that OLZ sensitization is a generalizable 
phenomenon that can be observed in MIA animals, and that the CAR sensitization induced 
by repeated OLZ exposure is associated with changes in cell proliferation and survival 
within the DG of the hippocampus.
RESULTS
Experiment 1: Assessment of MIA behavioral alterations during early postnatal period and 
adulthood
We first established the validity of our MIA model by assessing phenotypic alterations at 
three time points: one day post PolyI:C treatment, early postnatal period, and adulthood. 
During gestation, we measured the percentage of pregnant dam weight change one day 
following saline or PolyI:C injection (Fig. 1a). One way ANOVA revealed a main effect of 
prenatal treatment, F(1,66)=10.910, p=0.002. This suggest that treatment of PolyI:C during 
gestation transiently decreased the amount of weight gain in pregnant females, 
demonstrating the effectiveness of PolyI:C.
Next, we further examined schizophrenia related phenotypes in MIA animals during the 
early postnatal period. Pup USV serve as an important communication tool from pups to 
mothers, and MIA is reported to cause an alteration in this behavior (Malkova et al, 2012). 
Here we assessed the number of maternal separation-induced USV made by pups on P11 
(Fig. 1b). Repeated measures two-way ANOVA revealed a main effect of call type, 
F(3,94)=53.75, p<0.001, and a call type × prenatal treatment interaction, F(3,94)=3.221, 
p=0.026. One way ANOVA on the individual call types revealed a main effect of prenatal 
treatment for long calls, F(1,98)=9.491, p=0.003 and total number of calls, F(1,98)=4.011, 
p=0.048. These findings strengthen the hypothesis that prenatal exposure to MIA may 
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impair pup social communications, and provide extended information on specific call type 
alterations.
Finally, as sensitivity to amphetamine is shown to be elevated in adult MIA offspring 
(Piontkewitz et al., 2011), we examined differences between prenatal treatment conditions in 
amphetamine-induced hyperlocomotion during adulthood. Figure 1c shows the mean 
locomotor activities as measured by the number of photobeam breaks throughout the 60-min 
test period after the amphetamine injections. Repeated measures two-way ANOVA revealed 
a main effect of time blocks, F(11,30)=14.001, p<0.001, and a marginal effect of prenatal 
treatment, F(1,40)=3.925, p=0.054. These findings suggest that prenatal exposure to MIA 
increased sensitivity to amphetamine in adult offspring, mimicking increased vulnerability 
to psychotomimetic drugs.
Experiment 2: Evaluation of OLZ sensitization in the conditioned avoidance response test 
and hippocampal cell proliferation and survival in MIA and saline rats
Using the validated MIA model, we next examined OLZ sensitization using the CAR test. 
The procedure consisted of four phases: avoidance training, post training PPI assessment, 
induction of OLZ sensitization, and expression of OLZ sensitization.
The first phase of CAR testing is the avoidance training. Repeated measures two-way 
ANOVA of percentage avoidance responses throughout the 10 CAR training days revealed 
only a main effect of day, F(9,82)=25.224, p<0.001, but no main effect of prenatal treatment 
(Fig. 2a). While performance from the first two days of CAR training suggests possible 
differences, the effect is not significant.
Following 10 days of avoidance training, all animals were assessed for PPI to examine 
differences in sensorimotor gating functions. Figure 2b and 2c shows the percentage of PPI 
and the magnitude of ASR one day following CAR training (P 43), respectively. There was 
no main effect of prenatal treatment on PPI, nor a prenatal treatment × prepulse level 
interaction. There was also no significant difference between the ASR of the two conditions.
Next, animals underwent five days of OLZ administration for induction of drug 
sensitization. Figure 3a and b shows the percentage of avoidance responses throughout the 
five test days. During this sensitization induction phase, OLZ treatment consistently 
disrupted avoidance response. Repeated measures two-way ANOVA analysis on the overall 
avoidance data for each drug treatment condition revealed a main effect of day, 
F(4,83)=25.301, p<0.001, drug groups, F(2,86)=426.523, p<0.001, and a significant day × 
drug group interaction, F(8,168)=3.111, p=0.003 (Fig. 3b). Post hoc LSD tests revealed that 
the 3 drug groups all differed significantly from each other, all p<0.001. There was no 
significant difference between prenatal treatments (Fig. 3a).
Prior to challenging the animals with low dose OLZ to assess sensitization expression, all 
animals underwent two days of drug free retraining sessions, the first with only the 
conditioned stimulus of noise present, and the second session with both the conditioned 
stimulus of noise and the unconditioned stimulus of shock. This ensured that all animals 
return to a high baseline of CAR behavior before the OLZ challenge. Figure 3c and d shows 
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the percentage of avoidance responses on the two retraining days and the OLZ sensitization 
challenge day. There was no group difference on the retraining days between prenatal 
treatment and drug groups, although repeated measures two-way ANOVA of the retraining 
days did reveal a main effect of day, F(1,86)=30.747, p<0.001.
Finally, after two days of drug free sessions, animals were challenged with OLZ 0.5 mg/kg 
to assess the expression of OLZ sensitization. Multifactorial ANOVA revealed a significant 
effect of drug group, F(2,86)=26.749, p<0.001 (Fig. 3). Post hoc LSD tests showed that the 
OLZ 1.0 and 2.0 mg/kg groups were significantly lower in percent avoidance than the VEH 
group, p<0.001 for both, confirming the OLZ sensitization effect. The two OLZ groups did 
not differ significantly from each other. There was also no significant difference between 
prenatal treatments (Fig. 3d). These results suggest that the OLZ sensitization is a general 
behavioral pharmacological phenomenon irrespective of prenatal treatment conditions.
To assess the relationship between OLZ sensitization and hippocampal cell proliferation and 
survival, all animals were sacrificed after the OLZ challenge, and 5′-bromodeoxyuridine 
(BrdU) immunoreactivity was measured. Figure 4a depicts a sample micrograph of BrdU 
labeling in the subgranular zone of the hippocampal dentate gyrus.
Cell proliferation was assessed in animals injected with BrdU during the drug free retraining 
days, while survival was assessed in animals injected with BrdU immediately prior to the 
repeated drug test days. Separate repeated two-way ANOVAs found no significant 
difference in the number of BrdU+ cells between prenatal or drug treatment groups in both 
cell proliferation (Fig. 4b) or short term cell survival (Fig. 4c). Interestingly, however, there 
was a differential association between OLZ sensitization and cell proliferation between the 
MIA and SAL offspring. While the magnitude of OLZ sensitization from day one to two of 
drug administration had no correlation with the number of BrdU+ cells assessed for 
proliferation (Fig. 4d, Person’s r=−0.005, p=0.983) in SAL animals, the highest percent 
avoidance suppression from day one to two of drug administration corresponded to the 
highest number of BrdU+ cells (Fig. 4e, Pearson’s r=0.527, p=0.030) in MIA animals 
injected with BrdU 48 hours prior to sacrifice. On the contrary, correlational analysis further 
revealed a different pattern of association between the magnitude of OLZ sensitization and 
short term cell survival between MIA and SAL animals. While the magnitude of OLZ 
sensitization from day one of drug administration to the challenge assessment had no 
correlation with the number of BrdU+ cells assessed for survival (Fig. 4f, Person’s r=0.162, 
p=0.533) in MIA animals, the highest percent of avoidance suppression from day one of 
drug administration to the challenge assessment corresponded to the lowest number of BrdU
+ cells in SAL animals injected with BrdU 9 days prior to sacrifice (Fig. 4g; Pearson’s r= 
−0.910, p<0.001). These results suggest that the magnitude of OLZ sensitization, as assessed 
by the extent of the CAR disruption over days, is associated with the increase in acute cell 
proliferation rate for MIA animals and the decrease in short term cell survival rate for SAL 
animals.
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DISCUSSION
The present study investigated the association between hippocampal cell growth and 
survival and adolescent OLZ sensitization in the CAR test using the MIA model of SZ. We 
found decreased pup USV and increased amphetamine sensitivity in MIA animals, 
validating that MIA animals do in fact display altered behaviors in preclinical assays 
relevant to SZ (Malkova et al, 2012; Piontkewitz et al, 2011). Using a two-phase paradigm 
we developed, we showed that repeated OLZ exposure sensitized MIA animals not only 
throughout the repeated drug test days, but also in the subsequent challenge test, with rats 
previously treated with OLZ having a stronger response to OLZ than drug naïve animals. So 
far, few groups have studied the effects of APD in MIA (Arad and Weiner, 2012; 
Piontkewitz et al, 2009, 2011, 2012b). Here we established that adolescent OLZ behavioral 
sensitization is a stable phenomenon irrespective of disease state. Furthermore, the present 
study extended our work on the neurobiological basis of OLZ sensitization by investigating 
hippocampal cellular changes (Zhao and Li, 2010; Zhao et al, 2012). The results indicated 
that cell proliferation correlated positively with the magnitude of OLZ induced CAR 
sensitization in MIA animals, while cell survival correlated negatively with sensitization 
magnitude in SAL animals.
MIA is a widely accepted disease model of SZ (Meyer and Feldon, 2010; Patterson, 2009). 
Epidemiological surveys in the human population indicate that bacterial and viral infections 
during the second trimester increase the risk of neurodevelopmental psychiatric disorders in 
the offspring by two fold (Boksa, 2008; Brown, 2006; Brown et al, 2000). These infections 
may activate the mother’s immune system, increasing cytokine expressions, disrupting 
offspring neurodevelopment, and causing SZ related phenotypes (Meyer and Feldon, 2009; 
Smith et al, 2007). Preclinical studies show that in utero exposure to immunostimulants such 
as lipopolysaccharide (LPS) and PolyI:C disrupts SZ relevant behaviors, including latent 
inhibition ([LI]; Meyer et al, 2010; Zuckerman and Weiner, 2003; Zuckerman et al, 2003), 
amphetamine-induced hyperlocomotion (Vorhees et al, 2012; Zager et al, 2012), and 
sensory-motor gating (Basta-Kaim et al, 2012; Wolff and Bilkey, 2008). Here we showed 
that rat pups prenatally exposed to PolyI:C exhibited abnormal USV patterns on P11 after 20 
minutes of maternal separation. So far there have been few studies that assessed this social 
communication deficit (Malkova et al, 2012; Yee et al, 2012), and our results complement 
current knowledge with detailed analyses of the call types, namely the long, short, and 
frequency modulating calls in the 40kHz range of pup vocalizations (Brudzynski et al, 1999; 
Ming et al, 2011). While PolyI:C offspring made fewer calls overall, the number of long 
calls were especially decreased in MIA offspring compared to control animals. In addition, 
our findings of increased amphetamine-induced hyperlocomotion in adult MIA animals are 
consistent with others (Meyer et al, 2010; Vorhees et al, 2012; Zager et al, 2012; 
Zuckerman et al, 2003). On instrumental learning and pre-attentive processing, we found no 
differences between adolescent control and MIA animals in either CAR acquisition or PPI, 
though the first and second days of avoidance training suggested a lower performance in the 
MIA group. Various reviews have alluded to differences in MIA procedures and age of 
assessment as sources of discrepancies (Fortier et al, 2007; Meyer and Feldon, 2012). For 
example, Basta-Kaim et al, 2012 saw PPI deficits in offspring exposed to LPS only on P90, 
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but not P30, while Wolff and Bilkey, 2010 observed PPI deficits on P35 in offspring 
exposed to PolyI:C. In learning, Zuckerman et al, 2003 found LI disruption in 3 month-old 
offspring, but not P35. Meyer et al, 2006 further confirmed that behavioral inconsistencies 
may be attributed to MIA timing, as offspring from dams treated with PolyI:C on G6, 9, and 
13 exhibited LI deficits, but not those on G17. These discrepancies suggest that while MIA 
is a valid preclinical model, different manipulations can produce variable results.
In this study, we demonstrated behavioral sensitization to repeated OLZ exposure in MIA 
offspring using the CAR assay, as we have previously shown in normal animals (Mead and 
Li, 2010; Qiao et al, 2013a; Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li, 
2012). As most patients on APD receive chronic treatments (Kalverdijk et al, 2008), and in 
recent years there has been a decrease in the age of treatment onset (Aparasu and Bhatara, 
2007; Olfson et al, 2006; Rani et al, 2008; Wong et al, 2004), preclinical studies addressing 
adolescent chronic APD use are critical for translational values. We have shown previously 
that repeated APD exposure alters the behavioral sensitivity of animals to subsequent 
treatments (Gao and Li, 2013; Mead and Li, 2010; Qiao et al, 2013a; Qin et al, 2013; 
Swalve and Li, 2012), and that this phenomenon is persistent from adolescence to adulthood 
(Qiao et al, 2013a, 2013b). Here we further determined that OLZ sensitization is 
independent of the disease state of the animal, suggesting that long term neural changes can 
occur rapidly with repeated APD exposure in this population also.
Using a pharmacological approach, we previously identified that dopamine D2 and serotonin 
(5HT) 2a receptors are involved in APD sensitization (Li et al, 2010, 2012; Qiao et al, 
2014). The current study targeted hippocampal cell growth as a potential contributor. While 
APD are largely developed according to DA and 5HT receptor antagonism, changes in cell 
growth and survival may be of significance in enhancing therapeutic efficacy. Current 
literature regarding this issue remains inconsistent, perhaps due to discrepancies in 
paradigms, dosages, and assessment time points (Keilhoff et al, 2012). For example, Halim 
et al, 2004 found that 28 days of clozapine (CLZ) increased dentate gyrus (DG) cell 
proliferation in healthy animals, but not survival. In contrast, Maeda et al, 2007 showed that 
while 14 days of CLZ protected against PCP-impaired cell proliferation, CLZ alone 
produced no change. Here we identified correlations between cellular measures and OLZ 
sensitization. Namely, that sensitization is positively correlated with cell proliferation for 
MIA animals and negatively correlated with survival for SAL animals.
In the present work, the number of BrdU-labeled cells that survived for nine days in SAL 
animals correlated negatively with the magnitude of OLZ sensitization. Here, a larger 
decrease in avoidances over days corresponded with a smaller number of newborn cells that 
survived, suggesting that individual OLZ sensitivity is associated with drug-related changes 
in cell survival. In addition, the number of BrdU-labeled cells two days post injections 
correlated positively with the magnitude of avoidance suppression (i.e. OLZ sensitization in 
CAR) in MIA animals. Thus, a larger decrease in avoidances over days corresponded with a 
larger number of newborn cells, suggesting that individual OLZ sensitivity in MIA is 
associated with drug-related changes in cell growth. The increase in MIA cell proliferation 
echoes previous findings(Halim et al, 2004; Kodama et al, 2004). For example, Kodama et 
al, 2004 showed that 21 days of OLZ treatment in healthy subjects was able to increase cell 
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proliferation in the DG. Here, our concurrent examination of hippocampal cellular changes 
and behavioral responsiveness suggests that differential sensitivity to OLZ is associated with 
individual variability in cell growth and pruning. As patient evaluation studies such as 
Stroup, 2007 indicate that patients with schizophrenia exhibit diverse reactions to APD 
treatment, our observation highlights the role of cell proliferation and survival as a marker of 
individual sensitivity to APD.
So far only Piontkewitz et al, 2012b have explored the effects of APD on MIA hippocampal 
changes. While the group reported increased cell survival in MIA, the study assessed 
survival of cells born post-APD treatment and at three weeks post BrdU injection, thus 
differing from our cell survival throughout the drug treatment period. Our result of a positive 
correlation between the magnitude of OLZ behavioral sensitization and MIA hippocampal 
cell proliferation suggests possible differences in adolescent brain response to repeated OLZ 
exposure between disease and healthy animals despite similar behavioral outputs. Indeed, 
while Piontkewitz et al, 2012b did not examine cell proliferation, the authors found that 
risperidone differentially affected 21-day cell survival between adolescent MIA and control 
animals. The underlying mechanism of how APD treatment alters MIA cell proliferation and 
survival is unknown, and our findings suggest the increase in hippocampal cell proliferation 
as a possibility.
Various studies have considered the effects of APD on cell survival under different 
durations – 14, 21, or 28 days. The duration of nine days was fitting for this study as it 
covered only the CAR assessment and drug treatment period. This prevented potential 
environmental confounds post OLZ treatment and CAR testing. While no parametric study 
exists regarding the progression of hippocampal cell survival over time under the influence 
of APD, it is likely that APD related changes in cell survival vary over time.
One limitation of this study is the uncertainty of the phenotypes of BrdU+ cells. While the 
focus here was not to determine hippocampal cell proliferation and survival specific to the 
neuronal lineage, it is important to remember that hippocampal stem cells not only give rise 
to neurons, but various supporting cell types including oligodendrocytes and endothelial 
cells (Kodama et al, 2004; Wang et al, 2004). Some above-mentioned studies investigating 
APD and hippocampal alterations have found that most BrdU+ cells are also NeuN+. 
However, studies have also suggested that disease mechanisms of SZ may involve deficits in 
non-neuronal cells (Benes and Berretta, 2001; Zhang and Reynolds, 2002), lending the 
notion that proliferation of all cell types may contribute to APD therapeutic efficacy.
In summary, results from the current study provided clinically relevant information. First, 
we verified that OLZ behavioral sensitization occurs in a disease model of SZ, confirming 
that this phenomenon is irrespective of disease state and offers a reference in creating 
therapeutic regimen. Secondly, the association between the magnitude of behavioral 
sensitization and hippocampal cell proliferation and survival provides novel additional 
insight regarding mechanisms associated with APD sensitization. Further investigation into 
whether hippocampal cell proliferation and pruning are necessary and sufficient to induce 
APD sensitization and generate increased therapeutic efficacy may lead to superior 
pharmacological management.
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METHODS
Animals
Sixty-eight pregnant Sprague-Dawley dams from Charles River (Portage, MI; gestation day 
[G] 6 on delivery date) and their offspring were used. Pregnant dams were single housed in 
48.3 × 26.7 × 20.3 cm transparent polycarbonate cages under 12h light/dark conditions (light 
on between 0630 and 1830 h). Rat pups remained with dams until weaning (P21), upon 
which they were separated and housed two per cage in 182 × 50 × 188.1 cm transparent 
polysulfone individually ventilated cages. Room temperature was maintained at 22 ± 1°C 
with a relative humidity of 45–60%. Food and water was available ad libitum. All 
experiments were run during the light cycle. All procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln.
Drugs and choice of doses
Polyinosinic:polycytidylic acid (PolyI:C, 4.0 mg/kg, intravenous [iv]; Sigma Aldrich, St. 
Louis, MO) was dissolved in 0.9% saline. This dose of PolyI:C was chosen based on 
previous studies using the same dose and route of administration to generate schizophrenia-
like phenotypes (Piontkewitz et al, 2009, 2012a, 2012b; Wolff and Bilkey, 2008, 2010; Yee 
et al, 2012; Zuckerman and Weiner, 2005; Zuckerman et al, 2003). Olanzapine (OLZ) 0.5, 
1.0, and 2.0 mg/kg (subcutaneous [sc]; gifts from the NIMH drug supply program) were 
dissolved in distilled sterile water with 1.0–1.5% glacial acetic acid. The 1.0 and 2.0 mg/kg 
OLZ acutely inhibit CAR without inducing catalepsy based on our previous work (Feng et 
al, 2013; Li et al, 2004, 2007, 2009; Mead and Li, 2010; Qiao et al, 2013a, 2013b; Sun et al, 
2009; Zhang and Li, 2012; Zhao and Li, 2010). The lower challenge dose of 0.5 mg/kg OLZ 
has been successfully used in our previous studies (Mead and Li, 2010; Qiao et al, 2013a; 
Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li, 2012) and prevents the floor 
effect (i.e. a high dose may cause maximal avoidance disruption and obscures the 
sensitization effect). The injection solution of amphetamine (1.5mg/kg, sc; Sigma Aldrich, 
St. Louis, MO) was obtained by mixing the drug with 0.9% saline. The dosage was chosen 
based on previous work showing robust hyperlocomotion without severe stereotypy (Sun et 
al, 2009). PolyI:C, OLZ and amphetamine were all administered at 1.0 ml/kg. 5′-
bromodeoxyuridine (BrdU, 75 mg/kg, ip; Sigma Aldrich, St. Louis, MO) was dissolved in 
0.9% saline (10 mg/ml) and administered at 7.5 ml/kg. This dosage and administration 
protocol of BrdU was chosen based on previous studies indicating clear labeling of dividing 
cells (Halim et al, 2004; Maeda et al, 2007; Wang et al, 2004).
Prenatal treatment
Prenatal PolyI:C treatment was performed on G15, when pregnant dams were anesthetized 
with 3% isoflurane (Fisher Scientific, Denver, CO) in 98% O2 and given a single iv 
injection at the tail vein. Weight changes of pregnant dams were measured and recorded one 
day post PolyI:C administration. For control comparison, half of the G15 pregnant dams 
were injected with saline at the tail vein, creating offspring that served as control animals 
without prenatal immune activation.
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Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes (Med Associates, St. Albans, VT) were used. Each 
box (64 cm W × 24 cm D × 30 cm H from grid floor) was housed in a ventilated, sound-
insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was divided 
into two equal-sized compartments by a partition with an arch style doorway (15 cm H × 9 
cm D at base) and a barrier (4 cm H from grid floor) so that rats had to jump in order to 
cross from one compartment to the other. The grid floor consisted of 40 stainless-steel rods 
measuring 0.48 cm in diameter spaced 1.6 cm apart center to center, through which a 
scrambled footshock (unconditioned stimulus [US], 0.8mA, maximum duration: 5 s) was 
delivered by a constant current shock generator (Model ENV-410B) and scrambler (Model 
ENV-412). The rat location and crossings between compartments were monitored by a set of 
16 photobeams (ENV-256-8P) affixed at the bottom of the box (3.5 cm above the grid 
floor). Illumination was provided by two houselights mounted at the top of each 
compartment. The conditioned stimulus (CS; i.e. 76 dB white noise) was produced by a 
speaker (ENV 224 AMX) mounted on the ceiling of the cubicle, centered above the shuttle 
box. Background noise (~74 dB) was provided by a ventilation fan affixed at the top corner 
of each isolation cubicle. All training and testing procedures were controlled by Med 
Associates programs running on a computer.
Pup ultrasonic vocalization (USV) recording apparatus
In each CAR box, an USV microphone (P 48/Emkay Microphone, Avisoft Bioacoustics, 
Berlin, Germany) was mounted on the ceiling of the two-compartment chamber. The 
microphone was connected via an E-MU 0404 USB Audio device to a computer. Acoustic 
data were displayed in real time by the Avisoft RECORDER, a multi-channel triggering 
hard-disk recording software (version 3.4; Avisoft Bioacoustics), and were recorded at a 
sampling rate of 192 kHz in 16 bit format. For acoustical analysis, recordings were 
transferred to Avisoft SASLab Pro (Version 4.51) and a fast Fourier transformation (FFT) 
was conducted. Spectrograms were generated with an FFT-length of 256 points and a time 
window overlap of 50% (100% Frame, FlatTop window). The spectrogram was produced at 
a frequency resolution of 750 Hz and a time resolution of 0.6667 ms. Call detection was 
provided by an automatic single threshold-based algorithm (threshold: −20 dB) and a hold-
time mechanism (hold time: 0.02 s).
Prepulse inhibition (PPI) of acoustic startle response (ASR) apparatus
The PPI test was performed using six Startle Monitor Systems (Kinder Scientific, Julian, 
CA). Each system, controlled by a PC, was housed in a compact sound attenuation cabinet 
(36 cm wide × 28 cm deep × 50 cm high). A speaker (diameter: 11 cm) mounted on the 
cabinet’s ceiling was used to generate acoustic stimuli (70 dB-120 dB). The startle response 
was measured by a piezoelectric sensing platform on the floor, which was calibrated daily. 
During testing, rats were placed in a rectangular box made of transparent Plexiglas (19 cm 
wide × 9.8 cm deep × 14.6 high) with an adjustable ceiling positioned atop the box, 
providing only limited restraint while prohibiting ambulation.
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Locomotor activity monitoring apparatus
Sixteen 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate activity boxes were housed 
in a quiet room. Each was equipped with a row of 6 photocell beams (7.8 cm between two 
adjacent photobeams) placed 3.2 cm above the floor of the cage. A computer with recording 
software (Aero Apparatus Sixbeam Locomotor System v1.4) was used to detect the 
disruption of the photocell beams and recorded the number of beam breaks.
Experiment 1: Assessment of MIA behavioral alterations during early postnatal period and 
adulthood
To establish the validity of our MIA model, we examined offspring behavior in two 
behavioral assays that have previously been reported to show abnormal phenotypes by MIA: 
pup USV (Malkova et al, 2012) and adult amphetamine-induced hyperlocomotion 
(Piontkewitz et al, 2011).
Pup USV induced by maternal separation—Pup USVs serve as an important social 
communication tool from pups to mothers. MIA is reported to cause an alteration in this 
behavior (Malkova et al, 2012). This experiment was designed to validate this behavioral 
abnormality associated with MIA. The procedure was similar to that previously used in our 
lab (Ming et al, 2011). Experimentally naïve rats (1 male and 1 female pup; SAL, n=50; 
MIA, n=50) from each litter was used on P11 for the experiment. Pups were separated from 
their dams and placed in plastics bowls (one pup per bowl, 14.5 and 9.0 cm wide at the top 
and bottom, 7.5 cm high) on heating pads (~35°C). Twenty minutes later, the bowls and 
pups were placed in the CAR chambers directly underneath the microphone. USV were 
recorded for 3 minutes. For acoustical analysis, recordings were transferred to Avisoft 
SASLab Pro (Version 4.51) and a fast Fourier transformation (FFT) was conducted. 
Spectrograms were generated with an FFT-length of 256 points and a time window overlap 
of 50% (100% Frame, FlatTop window). The spectrogram was produced at a frequency 
resolution of 750 Hz and a time resolution of 0.6667 ms. Call detection was provided by an 
automatic dual threshold-based algorithm and a hold-time mechanism (hold time: 0.02 s). 
The primary threshold was defined at −40 dB, while the start/end threshold was defined at 
−20 dB. Pup USV were classified into three types by a custom-built computer program. 
“Long” USV were defined as waveforms that were greater than 50 ms long, with a 
frequency deviation of less than 3 kHz. “Short” USV weny waveforms that were less than 
50 ms long. “Frequency-modulated” USV were greater than 50 ms long and had a frequency 
deviation of greater than 3 kHz. A comparison between this automatic quantification method 
and human scoring on four randomly selected tests revealed a high degree of agreement, 
with a Pearson’s product moment correlation ranging from 0.979 to 0.998.
Adult amphetamine-induced hyperlocomotion—Sensitivity to amphetamine is 
elevated in adult MIA offspring as a measure of hyperDAergic function (Piontkewitz et al., 
2011). This experiment examined possible differences between prenatal treatment 
conditions in amphetamine-induced hyperlocomotion during adulthood. Separate groups of 
male and female adult offspring that were not used in OLZ testing were tested on P84, 
which also include some rats tested for pup USVs. The procedure was similar to that 
previously used in our lab (Sun et al, 2009). Rats were first habituated to the locomotor 
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activity apparatus for 30 min. They were then taken out of the activity monitoring boxes, 
injected with 0.9% saline and replaced immediately back into the boxes. At the end of 
another 30 min period, rats were taken out and injected with amphetamine and placed back 
in the boxes for another 60 min. Locomotor activity (number of photobeam breaks) was 
measured and recorded in 5 min intervals throughout the entire 120 min testing session.
Experiment 2: Evaluation of OLZ sensitization and hippocampal cell proliferation and 
survival in the conditioned avoidance response test using MIA and control animals
This experiment examined whether OLZ sensitization was differentially expressed in the 
MIA and saline male rats and whether cell proliferation in the dentate gyrus (DG) was 
altered by OLZ exposure to mediate OLZ sensitization in the CAR test. No more than 2 
male pups from each litter were used in this experiment in order to minimize litter effects 
(Zorrilla, 1997). The overall experimental procedure was similar to that previously reported 
(Mead and Li, 2010; Qiao et al, 2013a; Swalve and Li, 2012) and consisted of four phases: 
avoidance training, post training PPI assessment, induction of OLZ sensitization, OLZ 
sensitization assessment, and cell proliferation and survival assay by BrdU 
immuohistochemistry
Avoidance training—Adolescent Sprague-Dawley males (P31) were first habituated to 
the CAR boxes for 2 days (30min/day) and then trained for conditioned avoidance 
responding for 10 consecutive days/sessions. Each session consisted of 30 trials. Every trial 
started by presenting a white noise (CS) for 10s, followed by a continuous scrambled foot 
shock (0.8 mA, US, maximum duration = 5 s) on the grid floor. An avoidance response was 
recorded if the subject crosses into the adjacent compartment within the duration of the CS 
presentation. An escape response was recorded if the subject crosses into the adjacent 
compartment during the US presentation. If the rat made no response throughout both CS 
and US, the trial was terminated and recorded as an escape failure. The total number of 
avoidance responses was recorded for each session. Inter-trial intervals varied randomly 
between 30 and 60s.
PPI of ASR assessment—One day after the CAR training (P43), rats were tested for a 
single session of PPI in order to examine possible differences between prenatal treatment 
conditions. Rats were placed in the PPI boxes and tested according to procedures adapted 
from Culm and Hammer, 2004. The PPI session lasted approximately 18 min and began 
with a 5 min period of 70 dB background noise that continued throughout the duration of the 
session. The 5 min background was followed by four different trial types: PULSE ALONE 
trials and three types of PREPULSE+PULSE trials, which consisted of a 20 ms 73, 76, or 82 
dB prepulse (3, 6, and 12 dB above background) followed 100 ms later by a 120 dB pulse. 
The session was divided into 4 blocks. Blocks 1 and 4 were identical, each consisting of 4 
PULSE ALONE trials. Blocks 2 and 3 were also identical and each consisted of 8 PULSE 
ALONE trials and 5 of each PREPULSE+PULSE trial type. A total of 54 trials were 
presented. Trials within each block were presented in a pseudorandom order and were 
separated by a variable intertrial interval averaging 15 s (ranging from 9 to 21 s). Startle 
magnitude of the acoustic startle response (ASR) was defined as the maximum force 
(measured in Newtons) applied by the rat to the startle apparatus recorded over a period of 
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100 ms beginning at the onset of the pulse stimulus. Between each stimulus trial, 100 ms of 
activity was recorded when no stimulus was present. These trials were called NOSTIM trials 
and were not included in the calculation of intertrial intervals. Responses recorded during 
NOSTIM trials are considered a measure of gross motor activity within the PPI boxes. 
Startle responses from testing blocks 2 and 3 were used to calculate percent prepulse 
inhibition (%PPI) for each acoustic prepulse trial type:
Repeated OLZ testing in CAR (i.e. induction phase of sensitization) (P 44–48)
—Following PPI assessment (P44), rats were assigned to one of three drug treatment 
groups: vehicle (VEH, 1% glacial acetic acid in sterile water), OLZ 1.0 mg/kg, and OLZ 2.0 
mg/kg and tested daily for avoidance response for 5 consecutive days. Rats were assigned 
such that offspring from the same litter were placed in different groups to minimize litter. 
The complete factorial design thus consisted of two prenatal treatments (MIA and saline 
offspring) × three drug doses (VEH, OLZ 1.0 mg/kg, and OLZ 2.0 mg/kg), with the saline 
offspring treated with vehicle during adolescence serving as the main control comparison 
group. The CS-only (no shock, 30 trials/daily session) condition was used to eliminate any 
relearning effect caused by the presence of the US. During each drug test, rats were first 
injected with OLZ or VEH and placed in the CAR boxes and tested 1 h later.
OLZ challenge test (i.e. expression phase of sensitization) (P51)—At the end of 
the drug test session (P49) all rats were retrained drug-free for two days, the first under CS-
only condition (no shock) and the second under CS-US, to ensure all groups had a 
comparable level of avoidance responding before the sensitization assessment. OLZ 
sensitization was assessed 1 day later (P51), when all rats were injected with a challenge 
dose of OLZ 0.5 mg/kg and tested for avoidance performance 1 h later.
BrdU immunohistochemistry for hippocampal cell proliferation and survival—
The BrdU immunohistochemistry technique was modified based on Cameron, 2006. Half of 
the animals in each prenatal and drug treatment group received 3 BrdU injections spaced 2 h 
apart following the PPI assessment (P43), while the other half received the injections on the 
first CAR retraining day (P49). The P43 injection allowed for short term cell survival 
assessment as the animals were sacrificed nine days later, while the P49 injection allowed 
for cell proliferation assessment as the animals were sacrificed after 48 hours. BrdU is a 
synthetic thymidine analogue preferentially incorporated into actively replicating cells. It is 
commonly used as a measure of cell proliferation as well as cell survival depending on the 
duration between BrdU injection and the time of examination of BrdU immunoreactivity in 
tissues (Gratzner, 1982).
The time points chosen in the current study is based on two considerations. First, for cell 
proliferation, we chose to inject BrdU 48 hours prior to sacrifice, one day after the last day 
of repeated OLZ administration, and animals were immediately sacrificed after the final 
OLZ challenge test. This allows for examination of how repeated OLZ treatment affects cell 
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proliferation without the contamination of the acute effect of OLZ exposure in the last 
challenge, as the time between challenge and sacrifice is too short for complete mitosis. 
Secondly, for cell survival, we chose to inject BrdU 9 days prior to sacrifice, one day prior 
to the start of repeated OLZ administration. This allows for examination of how repeated 
OLZ treatment affects cell survival without the contamination of other environmental factors 
post repeated treatment to alter cell survival. The durations were also chosen based on a 
parametric study by Dayer et al, 2003. The study concluded that BrdU signals two days post 
injection were highly co-expressed with Ki-67, a marker present in cells in all active phases 
of the cell cycle, and also frequently used as a marker of cell proliferation (Kee et al, 2002; 
Muskhelishvili et al, 2003). This suggests that BrdU+ cells identified two days post BrdU 
injection are representative of actively dividing cells (i.e. cell proliferation). The study also 
concluded that BrdU signals eight days post injection were not co-expressed with Ki-67, 
indicating that these cells were no longer in the mitotic phase and not representative of 
newly added daughter cells. This suggests that BrdU+ cells identified at eight days (nine in 
the current study) post BrdU injection are representative of cells that survived after leaving 
the cell cycle.
Following OLZ sensitization challenge test (P51), all rats were deeply anesthetized with 
sodium pentobarbital (100.0 mg/kg, ip) and transcardially perfused with 0.02M phosphate 
buffered saline (PBS) followed by 4% paraformaldehyde (PFA, pH 7.4) in 0.1M PBS. 
Brains were then harvested, post-fixed in 4% PFA overnight and cryoprotected in 30% 
sucrose for 72 hours. Serial coronal sections (35μm) of the hippocampus (Bregma −2.0 to 
−4.5; Paxinos and Watson, 2007) were cut on a cryostat, and every twelfth section in series 
(6 sections per animal) were processed for BrdU labeling. Free floating sections were 
incubated in 2M HCl at 37°C for 30 min, followed by two 15 min incubations of 40mM 
borate buffer. Sections were then incubated in blocking solution (0.3% Triton X-100 and 
10% normal horse serum in 0.02M PBS) for 1 h, followed by 3% H2O2 with 100% methanol 
for 30 min, and then in primary antibody at 4°C overnight (mouse anti-BrdU, 1:15,000; 
Millipore, Billerica, MA). Secondary antibody (biotinylated horse anti-mouse IgG, 1:500; 
Vector Laboratories, Burlingame, CA) incubated sections for 1 h, followed by avidin-
biotinylated enzyme complex (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, 
CA) for another hour. 3,3′-diaminobenzidine (DAB peroxidase substrate, Vector 
Laboratories, Burlingame, CA) was used to reveal BrdU labeling. Normal horse serum 
substitution for primary antibody was used as negative control.
Cell counting was conducted by an experimenter blinded to the conditions. Cells were 
viewed with an Olympus CX41RF microscope (Japan) under 200× magnification, and those 
with clear delineation of staining in the granule cell layer of the hippocampal DG were 
counted. A modified stereological procedure adapted from previous reports (Cameron and 
McKay, 2001; Eisch et al, 2000; Gould et al, 1999; Malberg et al, 2000; West et al, 1991) 
was used for analysis, which consisted of counting all BrdU-labeled cells bilaterally for each 
section, then multiplying the sum of the 6 sections by 12 in order to estimate the total 
number of BrdU+ cells per DG.
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Statistical analysis
All data were expressed as mean ± standard error of mean. One way analysis of variance 
(ANOVA) was used to compare pregnant dam weight changes one-day after PolyI:C or 
saline treatment. Repeated measures two-way ANOVA (between-subjects factor: prenatal 
treatment; within-subjects factor: call type) was conducted on pup USV. Repeated measures 
two-way ANOVA (between-subjects factor: prenatal treatment or drug groups; within-
subjects factor: days) was also used for CAR training and drug test sessions. In addition, 
percent PPI data for the 3 prepulse intensities (e.g. 73, 76 and 82 dB) were analyzed with 
repeated measures two-way ANOVA (between-subjects factor: prenatal treatment; within-
subjects factor: prepulse types). Data from CAR retraining, sensitization assessment, and 
cell counting were analyzed by multi-factorial ANOVA (prenatal treatment × drug groups). 
Pearson product-moment correlational analysis was conducted between percentage of 
avoidance suppression, as assessed by calculating the percent decrease in the number of 
avoidances made during either day two of drug administration or challenge day compared to 
day one of drug administration, and number of BrdU+ cells. All significant differences were 
followed by post hoc LSD tests. For all analyses, p < 0.05 was considered statistically 
significant.
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Highlights
1. Adolescent olanzapine use causes sensitization in immune activated offspring.
2. Sensitization magnitude correlates negatively with cell survival in controls.
3. Magnitude correlates positively with cell growth in immune activated offspring.
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Figure 1. 
Assessment of MIA induced alterations in infancy and adulthood. Percentage of pregnant 
dam weight changes one day following saline (SAL) or PolyI:C (MIA) treatment on G15 
(a). Maternal separation induced pup ultrasonic vocalizations on P11 (b). Numbers of 
ultrasonic vocalizations for each call type (short, long, frequency modulating [mod], total) 
made by offspring from the prenatal SAL and MIA treatment groups. Amphetamine-induced 
hyperlocomotion on P84 (c). Mean locomotor activities measured as numbers of photobeam 
breaks during the 60-min test period after the amphetamine injection made by offspring 
from the prenatal SAL and MIA treatment groups. All data are expressed as mean ± SEM. 
*p<0.005 and &p=0.054 between prenatal treatment conditions; **p<0.001 between call 
types; ##p<0.005 and #p<0.05 relative to the saline group.
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Figure 2. 
Conditioned avoidance response acquisition. Percentages of avoidance responses made by 
offspring from the prenatal SAL and MIA treatment groups during the ten days of 
conditioned avoidance training (a). Prepulse inhibition (b) and acoustic startle response (c) 
assessment post conditioned avoidance response training. All data are expressed as mean ± 
SEM. *p<0.05 between prenatal treatment conditions.
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Figure 3. 
Olanzapine sensitization and assessment. Repeated olanzapine administration in conditioned 
avoidance response (a,b). Percentages of avoidance responses made by rats from each drug 
group (VEH, OLZ 1.0, and 2.0 mg/kg) in the two separate prenatal treatment conditions (a, 
saline [SAL] and PolyI:C [MIA]) and with the prenatal conditions combined (b) throughout 
the five drug test days. Assessment of olanzapine sensitization in conditioned avoidance 
response (c,d). Percentages of avoidance responses made by rats from each drug group 
(VEH, OLZ 1.0 and 2.0 mg/kg) in the two separate prenatal treatment conditions (c, SAL 
and MIA) and with the prenatal conditions combined (d) on the retraining days and the OLZ 
sensitization assessment day. All data are expressed as mean ± SEM. *p<0.001 between 
drug treatment conditions.
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Figure 4. 
BrdU analysis of olanzapine associated cell proliferation and survival. Sample micrograph 
of BrdU+ cells (dark brown) in the granule cell layer of the hippocampal dentate gyrus (a). 
Assessment of cell proliferation (b). Estimated numbers of BrdU+ cells throughout the entire 
dentate gyrus for animals in each prenatal and drug treatment condition treated with BrdU 
two days prior to sacrifice. Assessment of cell survival (c). Estimated numbers of BrdU+ 
cells throughout the entire dentate gyrus for animals in each prenatal and drug treatment 
condition treated with BrdU nine days prior to sacrifice. All data in b and c are expressed as 
mean ± SEM. Correlational analyses of olanzapine sensitization and cell proliferation in the 
hippocampal dentate gyrus (d,e). Number of BrdU+ cells two days post BrdU injection was 
positively associated with the percent of avoidance suppression induced by olanzapine in 
MIA offspring, r=0.527, p=0.030 (e). Correlational analyses of olanzapine sensitization and 
cell survival in the hippocampal dentate gyrus (f, g). Number of BrdU+ cells nine days post 
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BrdU injection was negatively associated with the percent of avoidance suppression induced 
by olanzapine in SAL offspring, r= −0.910, p<0.001 (f).
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